Health disorders in women can be caused by many abnormalities in the body...
Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis
Skyrizi™ (risankizumab-rzaa) is a monoclonal antibody (mAb) indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients.
Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection
Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Balversa (erdafitinib) for the Treatment of Urothelial Carcinoma
Balversa™ (erdafitinib) is one of the first fibroblast growth factor receptor (FGFR) kinase inhibitors to be approved for the treatment of locally advanced or metastatic urothelial carcinoma.
Lamzede (velmanase alfa) to Treat Alpha-Mannosidosis
Lamzede® (velmanase alfa) is one of the first enzyme replacement therapies indicated for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha‑mannosidosis.
ImmunoPrecise to Lead Scientific Round-table Discussion
At hubXchange’s European Antibody Therapeutics event, Debby Kruijsen will lead a round-table discussion entitled 'Implementing discovery strategies to value the therapeutic potential of lead antibody candidates' while Nienke Smits will present a poster entitled 'DeepDisplay™: a powerful and unique human lead antibody discovery platform utilizing OmniMouse®'.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.